Tag: GlobeNewswire

To Nasdaq Copenhagen A/S 

                                                                                       2 November 2026
                                                                                       Announcement no. 93/2026

Jyske Realkredit’s auctions for 1 January 2027 refinancing

Jyske Realkredit plans to carry out the auction from Monday 16^th to Thursday 19^th of November 2026 for loans in cover pool E.

The refinancing amount and bonds to be offered are specified in the table below:

	Open	Close	Alloc.	Name	ISIN	Amount mill.	LCR
Monday 16 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Tuesday 17 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Wednesday 18 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Thursday 19 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B

Auction terms appear in the appendix.

Questions regarding the bond sale as well as technical matters may be addressed to Jyske Realkredit, Lars Hasløv, Head of Realkredit Treasury tel. (+45) 89 89 92 19 or Christian Bech-Ravn, Director, Head of Investor Relations, tel. (+45) 89 89 92 25.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

Yours sincerely,

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

Appendix – Auctions terms

Refinancing principles adjustable rate mortgage loans
Jyske Realkredit offers fixed-rate non-callable bonds for adjusting interest rates on the loans.

When adjusting the interest rates, the bonds are sold at one or more auctions. The price is determined as a weighted average of the prices obtained at the auctions.

Type of auction
The auction of bonds in capital centres E will be conducted on Bloomberg’s auction system.

Bids
Bids for the offered bonds must be made in terms of amount and price.

For bonds maturing within 14 months, bids must be made correct to three decimals. For other bonds, bids must be made with an accuracy of two decimals.

For all bonds bids must be made in multiples of DKK 1,000,000

Conditional offer for bonds with interest rate triggers
For the bonds offered with an interest rate trigger, it is a condition for the final completion of the sale (allotment) that there is no increase in interest rates of more than 5 percentage points. Reference is made to the Act on Mortgage Loans and Mortgage Bonds, etc.

Allotment
All bids above the cut-off price will be settled in full at the cut-off fixing spread. For bids at the exact cut-off price, proportional allocation may be used. No bids below the cut-off price will be settled.

All trades concluded will be published through Nasdaq Copenhagen.

Allotment at the auction will take place as soon as possible, and not later than 5 minutes after closing.

Value date
All bonds will be subject to long settlement. The value date of all trades executed at the auction will be 1^st of January 2027.

Reverse facility
As the bonds traded will be subject to long settlement, Jyske Realkredit offers a reverse facility to auction participants whose bids have been accepted and who require the bonds after only two days.

By means of the reverse facility, Jyske Realkredit offers to sell the allotted bonds subject to the conventional two settlement days and subsequently repurchase them with 1^st of January 2027 as the value date.

The size of the reverse facility will be determined on an individual basis but cannot exceed the amount allotted to each individual bidder.

The reverse facility can be made conditional on the investor providing a corresponding amount of Jyske Realkredit covered bonds (SDO) or mortgage bonds (RO) maturing on 1^st of January 2027 or a corresponding amount of DKK SDO/SDRO level 1B AAA rated covered bonds issued from other Danish mortgage institutions maturing on 1st of January 2027.

Reverse facilities will be arranged on an individual basis by contacting Jyske Realkredit

Credit Ratings
All auctioned bonds issued through Capital Centre E are rated AAA by S&P.

Reservations regarding auctions
If, contrary to expectations, technical problems should prevent Jyske Realkredit from conducting an auction through Bloombergs auction system, a stock ex-change announcement will be issued containing the practical details of the auction.

Other terms
Jyske Realkredit is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. If a sale of bonds has to be cancelled, the market will be notified immediately by a stock exchange announcement.

To Nasdaq Copenhagen A/S 

                                                                                       2 November 2026
                                                                                       Announcement no. 93/2026

Jyske Realkredit’s auctions for 1 January 2027 refinancing

Jyske Realkredit plans to carry out the auction from Monday 16^th to Thursday 19^th of November 2026 for loans in cover pool E.

The refinancing amount and bonds to be offered are specified in the table below:

	Open	Close	Alloc.	Name	ISIN	Amount mill.	LCR
Monday 16 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Tuesday 17 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Wednesday 18 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Thursday 19 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B

Auction terms appear in the appendix.

Questions regarding the bond sale as well as technical matters may be addressed to Jyske Realkredit, Lars Hasløv, Head of Realkredit Treasury tel. (+45) 89 89 92 19 or Christian Bech-Ravn, Director, Head of Investor Relations, tel. (+45) 89 89 92 25.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

Yours sincerely,

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

Appendix – Auctions terms

Refinancing principles adjustable rate mortgage loans
Jyske Realkredit offers fixed-rate non-callable bonds for adjusting interest rates on the loans.

When adjusting the interest rates, the bonds are sold at one or more auctions. The price is determined as a weighted average of the prices obtained at the auctions.

Type of auction
The auction of bonds in capital centres E will be conducted on Bloomberg’s auction system.

Bids
Bids for the offered bonds must be made in terms of amount and price.

For bonds maturing within 14 months, bids must be made correct to three decimals. For other bonds, bids must be made with an accuracy of two decimals.

For all bonds bids must be made in multiples of DKK 1,000,000

Conditional offer for bonds with interest rate triggers
For the bonds offered with an interest rate trigger, it is a condition for the final completion of the sale (allotment) that there is no increase in interest rates of more than 5 percentage points. Reference is made to the Act on Mortgage Loans and Mortgage Bonds, etc.

Allotment
All bids above the cut-off price will be settled in full at the cut-off fixing spread. For bids at the exact cut-off price, proportional allocation may be used. No bids below the cut-off price will be settled.

All trades concluded will be published through Nasdaq Copenhagen.

Allotment at the auction will take place as soon as possible, and not later than 5 minutes after closing.

Value date
All bonds will be subject to long settlement. The value date of all trades executed at the auction will be 1^st of January 2027.

Reverse facility
As the bonds traded will be subject to long settlement, Jyske Realkredit offers a reverse facility to auction participants whose bids have been accepted and who require the bonds after only two days.

By means of the reverse facility, Jyske Realkredit offers to sell the allotted bonds subject to the conventional two settlement days and subsequently repurchase them with 1^st of January 2027 as the value date.

The size of the reverse facility will be determined on an individual basis but cannot exceed the amount allotted to each individual bidder.

The reverse facility can be made conditional on the investor providing a corresponding amount of Jyske Realkredit covered bonds (SDO) or mortgage bonds (RO) maturing on 1^st of January 2027 or a corresponding amount of DKK SDO/SDRO level 1B AAA rated covered bonds issued from other Danish mortgage institutions maturing on 1st of January 2027.

Reverse facilities will be arranged on an individual basis by contacting Jyske Realkredit

Credit Ratings
All auctioned bonds issued through Capital Centre E are rated AAA by S&P.

Reservations regarding auctions
If, contrary to expectations, technical problems should prevent Jyske Realkredit from conducting an auction through Bloombergs auction system, a stock ex-change announcement will be issued containing the practical details of the auction.

Other terms
Jyske Realkredit is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. If a sale of bonds has to be cancelled, the market will be notified immediately by a stock exchange announcement.

• Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipeline
• Significantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunities
• Combined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) — Supernus, Inc. (Nasdaq: SUPN)¹ today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.

Supernus, Inc. Creates Immediate Scale and Expanded Capabilities

• A Diversified Commercial Platform: An 11-product portfolio spans opioid use disorder, psychiatry, and neurology, and includes five core growth drivers – SUBLOCADE^®, Qelbree^®, GOCOVRI^®, ONAPGO^®, and ZURZUVAE^® – that provide a durable foundation for long-term revenue expansion.
• Established Financial Scale and Enhanced Cash Flow: Financial capacity to pursue further growth opportunities, including driving growth in its commercial portfolio, advancing its novel pipeline, and pursuing future business.

“Today marks a transformative milestone as we officially bring together two organizations united by a shared dedication to those living with complex neurological conditions,” said Jack Khattar, President and CEO of Supernus, Inc. “As one team, we are committed to expanding meaningful treatments for patients, executing seamlessly, and delivering long-term value for our shareholders.”

Tony Kingsley, Chair of the Board of Directors of Supernus, Inc., added, “This combination brings together best-in-class commercial capabilities, leading CNS therapies, and a strong financial foundation. We believe the combined company is exceptionally well positioned to pursue long-term growth while maintaining disciplined capital allocation and a commitment to creating shareholder value.”

The Merger and Transaction Details
Under the terms of the definitive merger agreement, Supernus Pharmaceuticals, Inc. stockholders received 1.5401 common shares of Indivior Pharmaceuticals, Inc. for each share of Supernus Pharmaceuticals, Inc. they owned.

Stockholders of Indivior immediately prior to the closing of the merger will receive a one-time special cash dividend of $1.0 billion in the aggregate as previously announced. To finance the dividend to Indivior stockholders, the companies utilized a previously secured debt commitment of $650 million through a term loan facility provided by Citibank N.A., with the remaining portion funded by existing cash on hand of the combined company.

Upon the close of the transaction, former Indivior stockholders own approximately 56.5% of the combined company, and former Supernus Pharmaceuticals, Inc. stockholders own approximately 43.5% of the combined company, on a fully diluted basis.

Leadership and Governance
Supernus Pharmaceuticals’ current headquarters in Rockville, Md., will serve as the combined company’s global headquarters. Jack Khattar will serve as President, Chief Executive Officer and a member of the Board of Directors of the combined company, and Tony Kingsley, previously a member of Indivior’s Board of Directors, will serve as Board Chair. The combined company’s Board of Directors has a total of eight directors, including four directors from each of the legacy companies.

Advisors
Cantor Fitzgerald & Co. served as lead financial advisor to Supernus Pharmaceuticals. Wells Fargo also served as an additional financial advisor to Supernus Pharmaceuticals. Saul Ewing LLP served as legal counsel to Supernus Pharmaceuticals and Morgan Lewis UK served as legal advisors to Supernus Pharmaceuticals with respect to certain ex-US matters.

Jefferies LLC and Piper Sandler & Co. served as joint financial advisors to Indivior and Goodwin Procter LLP served as legal counsel to Indivior. Citi also provided financial advice to Indivior, and Citibank, N.A. provided committed financing in support of the transaction.

Additional information about the transaction can be found on the Supernus website, which is listed below.

About Supernus, Inc.
Supernus, Inc. is a leading, diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases.

Our commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Backed by strong commercial capabilities and scientific expertise, we are committed to continuous innovation, advancing a robust pipeline of novel product candidates to deliver meaningful outcomes for CNS patients.

For more information, please visit www.supernus.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements are based on Supernus’s current expectations, estimates, and assumptions and are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding: the expected benefits of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., including anticipated synergies, cost savings, enhanced cash flow, financial flexibility, and scale, and the timeframe for realizing them; the combined company’s positioning as a leading diversified central nervous system (CNS) biopharmaceutical company; the expectation that the combined company’s common stock will begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026, and the related delisting and relisting; the expected performance of the combined company’s 11-product portfolio and the potential of its five core growth drivers to provide a durable foundation for long-term revenue expansion; the combined company’s plans and capacity to advance its CNS pipeline, pursue strategic growth opportunities and future business development, and allocate capital in a disciplined manner to create shareholder value; the integration of the legacy Supernus and Indivior businesses; the timing and progress of clinical trials and the receipt and timing of regulatory approvals; the expansion of manufacturing capabilities, including manufacture of ONAPGO at a second supplier; and the combined company’s future financial performance and projected expenditures. Forward-looking statements also include any other statements that are not statements of historical fact, including those that use words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “outlook,” “forecast,” “guidance,” “may,” “will,” “would,” “could,” “should,” and similar expressions, although not all forward-looking statements contain these words.

All forward-looking statements involve risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: the risk that the anticipated benefits, synergies, and cost savings of the merger may not be realized within the expected timeframe or at all; the difficulties and costs of integrating the legacy businesses of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and the risk that the integration may divert management attention or disrupt operations or relationships with customers, payors, suppliers, or employees; the effect of the combined company’s indebtedness, including the term loan facility used to fund the special cash dividend, on its financial results; the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for, and net revenue from, each of its products and the products of its subsidiaries, and to commercialize those products; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates or to manufacture ONAPGO at the second supplier; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and to operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state, and foreign regulatory requirements; the therapeutic benefits, effectiveness, and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products, including ONAPGO, and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; changes to laws and regulations applicable to our industry; the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, and tariffs; and the other risks identified in the Company’s filings with the SEC.

These forward-looking statements speak only as of the date of this press release, and Supernus, Inc. undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

End note

(1) As part of the closing process, Supernus Pharmaceuticals, Inc. will be delisted from Nasdaq. The combined company, Supernus, Inc., is expected to trade under the ticker symbol SUPN beginning on November 3, 2026. The combined company, Supernus, Inc., will trade under the ticker symbol INDV on November 2, 2026.

Supernus, Inc. Contacts

Investors
Peter Vozzo 
ICR Healthcare 
+1 443 213 0505
peter.vozzo@icrhealthcare.com
     
Media
mediacontacts@supernus.com

• Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipeline
• Significantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunities
• Combined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) — Supernus, Inc. (Nasdaq: SUPN)¹ today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.

Supernus, Inc. Creates Immediate Scale and Expanded Capabilities

• A Diversified Commercial Platform: An 11-product portfolio spans opioid use disorder, psychiatry, and neurology, and includes five core growth drivers – SUBLOCADE^®, Qelbree^®, GOCOVRI^®, ONAPGO^®, and ZURZUVAE^® – that provide a durable foundation for long-term revenue expansion.
• Established Financial Scale and Enhanced Cash Flow: Financial capacity to pursue further growth opportunities, including driving growth in its commercial portfolio, advancing its novel pipeline, and pursuing future business.

“Today marks a transformative milestone as we officially bring together two organizations united by a shared dedication to those living with complex neurological conditions,” said Jack Khattar, President and CEO of Supernus, Inc. “As one team, we are committed to expanding meaningful treatments for patients, executing seamlessly, and delivering long-term value for our shareholders.”

Tony Kingsley, Chair of the Board of Directors of Supernus, Inc., added, “This combination brings together best-in-class commercial capabilities, leading CNS therapies, and a strong financial foundation. We believe the combined company is exceptionally well positioned to pursue long-term growth while maintaining disciplined capital allocation and a commitment to creating shareholder value.”

The Merger and Transaction Details
Under the terms of the definitive merger agreement, Supernus Pharmaceuticals, Inc. stockholders received 1.5401 common shares of Indivior Pharmaceuticals, Inc. for each share of Supernus Pharmaceuticals, Inc. they owned.

Stockholders of Indivior immediately prior to the closing of the merger will receive a one-time special cash dividend of $1.0 billion in the aggregate as previously announced. To finance the dividend to Indivior stockholders, the companies utilized a previously secured debt commitment of $650 million through a term loan facility provided by Citibank N.A., with the remaining portion funded by existing cash on hand of the combined company.

Upon the close of the transaction, former Indivior stockholders own approximately 56.5% of the combined company, and former Supernus Pharmaceuticals, Inc. stockholders own approximately 43.5% of the combined company, on a fully diluted basis.

Leadership and Governance
Supernus Pharmaceuticals’ current headquarters in Rockville, Md., will serve as the combined company’s global headquarters. Jack Khattar will serve as President, Chief Executive Officer and a member of the Board of Directors of the combined company, and Tony Kingsley, previously a member of Indivior’s Board of Directors, will serve as Board Chair. The combined company’s Board of Directors has a total of eight directors, including four directors from each of the legacy companies.

Advisors
Cantor Fitzgerald & Co. served as lead financial advisor to Supernus Pharmaceuticals. Wells Fargo also served as an additional financial advisor to Supernus Pharmaceuticals. Saul Ewing LLP served as legal counsel to Supernus Pharmaceuticals and Morgan Lewis UK served as legal advisors to Supernus Pharmaceuticals with respect to certain ex-US matters.

Jefferies LLC and Piper Sandler & Co. served as joint financial advisors to Indivior and Goodwin Procter LLP served as legal counsel to Indivior. Citi also provided financial advice to Indivior, and Citibank, N.A. provided committed financing in support of the transaction.

Additional information about the transaction can be found on the Supernus website, which is listed below.

About Supernus, Inc.
Supernus, Inc. is a leading, diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases.

Our commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Backed by strong commercial capabilities and scientific expertise, we are committed to continuous innovation, advancing a robust pipeline of novel product candidates to deliver meaningful outcomes for CNS patients.

For more information, please visit www.supernus.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements are based on Supernus’s current expectations, estimates, and assumptions and are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding: the expected benefits of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., including anticipated synergies, cost savings, enhanced cash flow, financial flexibility, and scale, and the timeframe for realizing them; the combined company’s positioning as a leading diversified central nervous system (CNS) biopharmaceutical company; the expectation that the combined company’s common stock will begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026, and the related delisting and relisting; the expected performance of the combined company’s 11-product portfolio and the potential of its five core growth drivers to provide a durable foundation for long-term revenue expansion; the combined company’s plans and capacity to advance its CNS pipeline, pursue strategic growth opportunities and future business development, and allocate capital in a disciplined manner to create shareholder value; the integration of the legacy Supernus and Indivior businesses; the timing and progress of clinical trials and the receipt and timing of regulatory approvals; the expansion of manufacturing capabilities, including manufacture of ONAPGO at a second supplier; and the combined company’s future financial performance and projected expenditures. Forward-looking statements also include any other statements that are not statements of historical fact, including those that use words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “outlook,” “forecast,” “guidance,” “may,” “will,” “would,” “could,” “should,” and similar expressions, although not all forward-looking statements contain these words.

All forward-looking statements involve risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: the risk that the anticipated benefits, synergies, and cost savings of the merger may not be realized within the expected timeframe or at all; the difficulties and costs of integrating the legacy businesses of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and the risk that the integration may divert management attention or disrupt operations or relationships with customers, payors, suppliers, or employees; the effect of the combined company’s indebtedness, including the term loan facility used to fund the special cash dividend, on its financial results; the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for, and net revenue from, each of its products and the products of its subsidiaries, and to commercialize those products; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates or to manufacture ONAPGO at the second supplier; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and to operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state, and foreign regulatory requirements; the therapeutic benefits, effectiveness, and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products, including ONAPGO, and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; changes to laws and regulations applicable to our industry; the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, and tariffs; and the other risks identified in the Company’s filings with the SEC.

These forward-looking statements speak only as of the date of this press release, and Supernus, Inc. undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

End note

(1) As part of the closing process, Supernus Pharmaceuticals, Inc. will be delisted from Nasdaq. The combined company, Supernus, Inc., is expected to trade under the ticker symbol SUPN beginning on November 3, 2026. The combined company, Supernus, Inc., will trade under the ticker symbol INDV on November 2, 2026.

Supernus, Inc. Contacts

Investors
Peter Vozzo 
ICR Healthcare 
+1 443 213 0505
peter.vozzo@icrhealthcare.com
     
Media
mediacontacts@supernus.com

• Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipeline
• Significantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunities
• Combined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) — Supernus, Inc. (Nasdaq: SUPN)¹ today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.

Supernus, Inc. Creates Immediate Scale and Expanded Capabilities

• A Diversified Commercial Platform: An 11-product portfolio spans opioid use disorder, psychiatry, and neurology, and includes five core growth drivers – SUBLOCADE^®, Qelbree^®, GOCOVRI^®, ONAPGO^®, and ZURZUVAE^® – that provide a durable foundation for long-term revenue expansion.
• Established Financial Scale and Enhanced Cash Flow: Financial capacity to pursue further growth opportunities, including driving growth in its commercial portfolio, advancing its novel pipeline, and pursuing future business.

“Today marks a transformative milestone as we officially bring together two organizations united by a shared dedication to those living with complex neurological conditions,” said Jack Khattar, President and CEO of Supernus, Inc. “As one team, we are committed to expanding meaningful treatments for patients, executing seamlessly, and delivering long-term value for our shareholders.”

Tony Kingsley, Chair of the Board of Directors of Supernus, Inc., added, “This combination brings together best-in-class commercial capabilities, leading CNS therapies, and a strong financial foundation. We believe the combined company is exceptionally well positioned to pursue long-term growth while maintaining disciplined capital allocation and a commitment to creating shareholder value.”

The Merger and Transaction Details
Under the terms of the definitive merger agreement, Supernus Pharmaceuticals, Inc. stockholders received 1.5401 common shares of Indivior Pharmaceuticals, Inc. for each share of Supernus Pharmaceuticals, Inc. they owned.

Stockholders of Indivior immediately prior to the closing of the merger will receive a one-time special cash dividend of $1.0 billion in the aggregate as previously announced. To finance the dividend to Indivior stockholders, the companies utilized a previously secured debt commitment of $650 million through a term loan facility provided by Citibank N.A., with the remaining portion funded by existing cash on hand of the combined company.

Upon the close of the transaction, former Indivior stockholders own approximately 56.5% of the combined company, and former Supernus Pharmaceuticals, Inc. stockholders own approximately 43.5% of the combined company, on a fully diluted basis.

Leadership and Governance
Supernus Pharmaceuticals’ current headquarters in Rockville, Md., will serve as the combined company’s global headquarters. Jack Khattar will serve as President, Chief Executive Officer and a member of the Board of Directors of the combined company, and Tony Kingsley, previously a member of Indivior’s Board of Directors, will serve as Board Chair. The combined company’s Board of Directors has a total of eight directors, including four directors from each of the legacy companies.

Advisors
Cantor Fitzgerald & Co. served as lead financial advisor to Supernus Pharmaceuticals. Wells Fargo also served as an additional financial advisor to Supernus Pharmaceuticals. Saul Ewing LLP served as legal counsel to Supernus Pharmaceuticals and Morgan Lewis UK served as legal advisors to Supernus Pharmaceuticals with respect to certain ex-US matters.

Jefferies LLC and Piper Sandler & Co. served as joint financial advisors to Indivior and Goodwin Procter LLP served as legal counsel to Indivior. Citi also provided financial advice to Indivior, and Citibank, N.A. provided committed financing in support of the transaction.

Additional information about the transaction can be found on the Supernus website, which is listed below.

About Supernus, Inc.
Supernus, Inc. is a leading, diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases.

Our commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Backed by strong commercial capabilities and scientific expertise, we are committed to continuous innovation, advancing a robust pipeline of novel product candidates to deliver meaningful outcomes for CNS patients.

For more information, please visit www.supernus.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements are based on Supernus’s current expectations, estimates, and assumptions and are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding: the expected benefits of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., including anticipated synergies, cost savings, enhanced cash flow, financial flexibility, and scale, and the timeframe for realizing them; the combined company’s positioning as a leading diversified central nervous system (CNS) biopharmaceutical company; the expectation that the combined company’s common stock will begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026, and the related delisting and relisting; the expected performance of the combined company’s 11-product portfolio and the potential of its five core growth drivers to provide a durable foundation for long-term revenue expansion; the combined company’s plans and capacity to advance its CNS pipeline, pursue strategic growth opportunities and future business development, and allocate capital in a disciplined manner to create shareholder value; the integration of the legacy Supernus and Indivior businesses; the timing and progress of clinical trials and the receipt and timing of regulatory approvals; the expansion of manufacturing capabilities, including manufacture of ONAPGO at a second supplier; and the combined company’s future financial performance and projected expenditures. Forward-looking statements also include any other statements that are not statements of historical fact, including those that use words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “outlook,” “forecast,” “guidance,” “may,” “will,” “would,” “could,” “should,” and similar expressions, although not all forward-looking statements contain these words.

All forward-looking statements involve risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: the risk that the anticipated benefits, synergies, and cost savings of the merger may not be realized within the expected timeframe or at all; the difficulties and costs of integrating the legacy businesses of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and the risk that the integration may divert management attention or disrupt operations or relationships with customers, payors, suppliers, or employees; the effect of the combined company’s indebtedness, including the term loan facility used to fund the special cash dividend, on its financial results; the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for, and net revenue from, each of its products and the products of its subsidiaries, and to commercialize those products; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates or to manufacture ONAPGO at the second supplier; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and to operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state, and foreign regulatory requirements; the therapeutic benefits, effectiveness, and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products, including ONAPGO, and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; changes to laws and regulations applicable to our industry; the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, and tariffs; and the other risks identified in the Company’s filings with the SEC.

These forward-looking statements speak only as of the date of this press release, and Supernus, Inc. undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

End note

(1) As part of the closing process, Supernus Pharmaceuticals, Inc. will be delisted from Nasdaq. The combined company, Supernus, Inc., is expected to trade under the ticker symbol SUPN beginning on November 3, 2026. The combined company, Supernus, Inc., will trade under the ticker symbol INDV on November 2, 2026.

Supernus, Inc. Contacts

Investors
Peter Vozzo 
ICR Healthcare 
+1 443 213 0505
peter.vozzo@icrhealthcare.com
     
Media
mediacontacts@supernus.com

MILWAUKEE, Nov. 02, 2026 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN) today announced that the Board of Directors (the “Board”) approved a regular quarterly cash dividend of $0.05 per share payable on December 1, 2026, to shareholders of record at the close of business on November 18, 2026.

About Twin Disc

Twin Disc, Inc. designs, manufactures, and sells marine and heavy-duty off-highway power transmission equipment. Products offered include: marine transmissions, azimuth drives, surface drives, propellers, and boat management systems, as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, control systems, and braking systems. The Company sells its products to customers primarily in the pleasure craft, commercial and military marine markets, as well as in the energy and natural resources, government, military and industrial markets. The Company’s worldwide sales to both domestic and foreign customers are transacted through a direct sales force and a distributor network. For more information, please visit www.twindisc.com.

Investors:

IMS Investor Relations

twindisc@imsinvestorrelations.com

Source: Twin Disc, Incorporated

MILWAUKEE, Nov. 02, 2026 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN) today announced that the Board of Directors (the “Board”) approved a regular quarterly cash dividend of $0.05 per share payable on December 1, 2026, to shareholders of record at the close of business on November 18, 2026.

About Twin Disc

Twin Disc, Inc. designs, manufactures, and sells marine and heavy-duty off-highway power transmission equipment. Products offered include: marine transmissions, azimuth drives, surface drives, propellers, and boat management systems, as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, control systems, and braking systems. The Company sells its products to customers primarily in the pleasure craft, commercial and military marine markets, as well as in the energy and natural resources, government, military and industrial markets. The Company’s worldwide sales to both domestic and foreign customers are transacted through a direct sales force and a distributor network. For more information, please visit www.twindisc.com.

Investors:

IMS Investor Relations

twindisc@imsinvestorrelations.com

Source: Twin Disc, Incorporated

• CEO Roger M. Perlmutter, M.D., Ph.D., to participate in Guggenheim 3^rd Annual Healthcare Innovation Conference Fireside Chat and JP Morgan Biotech Call series
• CMO Roy Baynes, M.D., Ph.D., to participate in Morgan Stanley Biotech Webcast discussing new data and the evolving synthetic lethality landscape

MILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics, will participate in the JP Morgan Chase Biotech Call series and a Guggenheim Investor Conference as listed below:

Event: JP Morgan Biotech Call Series
Location: Boston, MA
Date & Time: November 6, 2026 at 2:00 pm EST
Format: Presentation

Event: Guggenheim 3rd Annual Healthcare Innovation Conference
Location: Boston, MA
Date & Time: November 10, 2026 at 8:00 pm EST
Format: Fireside Chat

In addition, Chief Medical Officer, Roy Baynes, M.D., Ph.D., will participate in the Morgan Stanley Biotech Webcast in November:

Event: Post-ESMO: New Data & the Evolving Synthetic Lethality Landscape
Location: New York City, NY
Date & Time: November 3, 2026 at 10:30 am EST
Format: Call

Live audio/video webcasts of these presentations will be accessible through Eikon’s investor relations website at investors.eikontx.com, with an archived edition of the session available later that day and accessible for approximately 30 days after the live event.

About Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.

Forward-Looking/Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the potential to further develop Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives, including Eikon’s anticipated presentations at the 2026 ESMO Congress; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future.

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts:

Investors
Alfred “Freddie” Bowie, Ph.D., CFO
ir@eikontx.com

Media
Colin Sanford
colin@bioscribe.com

• CEO Roger M. Perlmutter, M.D., Ph.D., to participate in Guggenheim 3^rd Annual Healthcare Innovation Conference Fireside Chat and JP Morgan Biotech Call series
• CMO Roy Baynes, M.D., Ph.D., to participate in Morgan Stanley Biotech Webcast discussing new data and the evolving synthetic lethality landscape

MILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics, will participate in the JP Morgan Chase Biotech Call series and a Guggenheim Investor Conference as listed below:

Event: JP Morgan Biotech Call Series
Location: Boston, MA
Date & Time: November 6, 2026 at 2:00 pm EST
Format: Presentation

Event: Guggenheim 3rd Annual Healthcare Innovation Conference
Location: Boston, MA
Date & Time: November 10, 2026 at 8:00 pm EST
Format: Fireside Chat

In addition, Chief Medical Officer, Roy Baynes, M.D., Ph.D., will participate in the Morgan Stanley Biotech Webcast in November:

Event: Post-ESMO: New Data & the Evolving Synthetic Lethality Landscape
Location: New York City, NY
Date & Time: November 3, 2026 at 10:30 am EST
Format: Call

Live audio/video webcasts of these presentations will be accessible through Eikon’s investor relations website at investors.eikontx.com, with an archived edition of the session available later that day and accessible for approximately 30 days after the live event.

About Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.

Forward-Looking/Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the potential to further develop Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives, including Eikon’s anticipated presentations at the 2026 ESMO Congress; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future.

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts:

Investors
Alfred “Freddie” Bowie, Ph.D., CFO
ir@eikontx.com

Media
Colin Sanford
colin@bioscribe.com

SOUTHAMPTON, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) — Environmental Tectonics Corporation (OTCID: ETCC) (“ETC” or the “Company”) was named to TIME’s annual list of America’s Growth Leaders 2027, ranking 201 among the top 500 companies. This recognition distinguishes ETC for its outstanding growth, performance, and business momentum. 

TIME and market research firm Statista, determined America’s Growth Leaders through an analysis of publicly traded companies headquartered in the U.S. Each company was evaluated based on revenue growth, stock performance, and financial stability.

ETC was also recognized in the Philadelphia Business Journal’s 2026 FAST 50 list, which highlights the fastest-growing companies in the Greater Philadelphia region. This is the second consecutive year that the Company has been recognized, ranking seventh both years.

Robert Laurent, ETC’s President and CEO stated, “Being named one of TIME’s America’s Growth Leaders is an indicator of the success of the strategic efforts of our entire team, in each of our business units. We are equally honored to be recognized as one of the fastest growing companies in the Greater Philadelphia region for the second year in a row.”

About ETC

ETC designs, manufactures, and sells software-driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies. ETC’s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC’s headquarters is in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/.

Forward-looking Statements

This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements.

Contact:	Tim Kennedy, CFO
Phone:	(215) 355-9100
E-mail:	info@etcusa.com